Zai Lab Ltd

ZLAB

Equity

ISIN US98887Q1040 / Valor 38178853

NASDAQ (2024-09-18)

USD 21.22+2.17%

Zai Lab Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Zai Lab Ltd is an innovative biopharmaceutical company with a focus on developing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders. Headquartered in China and the U.S., the company is committed to bringing these medicines to patients globally. With a research-based approach, Zai Lab aims to leverage its China-based competencies and resources to make a significant impact on human health worldwide.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Zai Lab Ltd reported net product revenue of $100.1 million for the second quarter of 2024, marking a 45% year-over-year growth compared to the same period in 2023. When adjusted for constant exchange rates (CER), the growth was 47% year-over-year.

Net Loss

For the second quarter of 2024, Zai Lab Ltd recorded a net loss of $80.3 million, which is an improvement from the net loss of $120.9 million reported in the second quarter of 2023. This reduction in net loss indicates a positive trend in the company's financial health.

Product Sales

Sales of VYVGART® (efgartigimod alfa injection) contributed $23.2 million to Zai Lab Ltd's revenue in the second quarter of 2024. The company has raised its full-year revenue guidance for VYVGART to exceed $80.0 million, reflecting strong market performance.

Operating Expenses

Zai Lab Ltd's operating expenses for the second quarter of 2024 included $61.6 million in research and development costs and $79.7 million in selling, general, and administrative expenses. These figures represent a decrease in R&D expenses but an increase in SG&A expenses compared to the same period in 2023.

Cash Position

As of June 30, 2024, Zai Lab Ltd maintained a strong balance sheet with a cash position of $730.0 million. This is a slight decrease from the $750.8 million reported as of March 31, 2024, but it still indicates a robust liquidity position for the company.

Summarized from source with an LLMView Source

Key figures

-17.7%1Y

-83.5%3Y

-38.3%5Y

Performance

58.5%1Y

82.1%3Y

74.5%5Y

Volatility